Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network
The phase I component of a phase I/II study defined the recommended phase II dose and established the tolerability of nab-paclitaxel monotherapy in paediatric patients with recurrent or refractory solid tumours. The activity and safety of nab-paclitaxel monotherapy was further investigated in this p...
Ausführliche Beschreibung
Autor*in: |
Amoroso, Loredana [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2020 |
---|
Schlagwörter: |
---|
Umfang: |
9 |
---|
Übergeordnetes Werk: |
Enthalten in: The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study - Hamzah, N. ELSEVIER, 2018, Amsterdam [u.a.] |
---|---|
Übergeordnetes Werk: |
volume:135 ; year:2020 ; pages:89-97 ; extent:9 |
Links: |
---|
DOI / URN: |
10.1016/j.ejca.2020.04.031 |
---|
Katalog-ID: |
ELV050852124 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | ELV050852124 | ||
003 | DE-627 | ||
005 | 20230624170346.0 | ||
007 | cr uuu---uuuuu | ||
008 | 200722s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ejca.2020.04.031 |2 doi | |
028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001600.pica |
035 | |a (DE-627)ELV050852124 | ||
035 | |a (ELSEVIER)S0959-8049(20)30234-3 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
084 | |a 44.52 |2 bkl | ||
100 | 1 | |a Amoroso, Loredana |e verfasserin |4 aut | |
245 | 1 | 0 | |a Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network |
264 | 1 | |c 2020 | |
300 | |a 9 | ||
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a nicht spezifiziert |b z |2 rdamedia | ||
338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
520 | |a The phase I component of a phase I/II study defined the recommended phase II dose and established the tolerability of nab-paclitaxel monotherapy in paediatric patients with recurrent or refractory solid tumours. The activity and safety of nab-paclitaxel monotherapy was further investigated in this phase II study. | ||
650 | 7 | |a Paediatric |2 Elsevier | |
650 | 7 | |a Ewing sarcoma |2 Elsevier | |
650 | 7 | |a Rhabdomyosarcoma |2 Elsevier | |
650 | 7 | |a Solid tumour |2 Elsevier | |
650 | 7 | |a Neuroblastoma |2 Elsevier | |
650 | 7 | |a Albumin-bound paclitaxel |2 Elsevier | |
700 | 1 | |a Castel, Victoria |4 oth | |
700 | 1 | |a Bisogno, Gianni |4 oth | |
700 | 1 | |a Casanova, Michela |4 oth | |
700 | 1 | |a Marquez-Vega, Catalina |4 oth | |
700 | 1 | |a Chisholm, Julia C. |4 oth | |
700 | 1 | |a Doz, François |4 oth | |
700 | 1 | |a Moreno, Lucas |4 oth | |
700 | 1 | |a Ruggiero, Antonio |4 oth | |
700 | 1 | |a Gerber, Nicolas U. |4 oth | |
700 | 1 | |a Fagioli, Franca |4 oth | |
700 | 1 | |a Hingorani, Pooja |4 oth | |
700 | 1 | |a Melcón, Soledad G. |4 oth | |
700 | 1 | |a Slepetis, Ruta |4 oth | |
700 | 1 | |a Chen, Nianhang |4 oth | |
700 | 1 | |a le Bruchec, Yvan |4 oth | |
700 | 1 | |a Simcock, Mathew |4 oth | |
700 | 1 | |a Vassal, Gilles |4 oth | |
773 | 0 | 8 | |i Enthalten in |n Elsevier |a Hamzah, N. ELSEVIER |t The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |d 2018 |g Amsterdam [u.a.] |w (DE-627)ELV000241849 |
773 | 1 | 8 | |g volume:135 |g year:2020 |g pages:89-97 |g extent:9 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2020.04.031 |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ELV | ||
912 | |a SYSFLAG_U | ||
936 | b | k | |a 44.52 |j Therapie |x Medizin |q VZ |
951 | |a AR | ||
952 | |d 135 |j 2020 |h 89-97 |g 9 |
author_variant |
l a la |
---|---|
matchkey_str |
amorosoloredanacastelvictoriabisognogian:2020----:hsirslsrmpaeisuyoseshsftadfiayfekyapciaeipeitiptetwtrcretrercoyoitmusclaoainihh |
hierarchy_sort_str |
2020 |
bklnumber |
44.52 |
publishDate |
2020 |
allfields |
10.1016/j.ejca.2020.04.031 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001600.pica (DE-627)ELV050852124 (ELSEVIER)S0959-8049(20)30234-3 DE-627 ger DE-627 rakwb eng 610 VZ 44.52 bkl Amoroso, Loredana verfasserin aut Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network 2020 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The phase I component of a phase I/II study defined the recommended phase II dose and established the tolerability of nab-paclitaxel monotherapy in paediatric patients with recurrent or refractory solid tumours. The activity and safety of nab-paclitaxel monotherapy was further investigated in this phase II study. Paediatric Elsevier Ewing sarcoma Elsevier Rhabdomyosarcoma Elsevier Solid tumour Elsevier Neuroblastoma Elsevier Albumin-bound paclitaxel Elsevier Castel, Victoria oth Bisogno, Gianni oth Casanova, Michela oth Marquez-Vega, Catalina oth Chisholm, Julia C. oth Doz, François oth Moreno, Lucas oth Ruggiero, Antonio oth Gerber, Nicolas U. oth Fagioli, Franca oth Hingorani, Pooja oth Melcón, Soledad G. oth Slepetis, Ruta oth Chen, Nianhang oth le Bruchec, Yvan oth Simcock, Mathew oth Vassal, Gilles oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:135 year:2020 pages:89-97 extent:9 https://doi.org/10.1016/j.ejca.2020.04.031 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 135 2020 89-97 9 |
spelling |
10.1016/j.ejca.2020.04.031 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001600.pica (DE-627)ELV050852124 (ELSEVIER)S0959-8049(20)30234-3 DE-627 ger DE-627 rakwb eng 610 VZ 44.52 bkl Amoroso, Loredana verfasserin aut Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network 2020 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The phase I component of a phase I/II study defined the recommended phase II dose and established the tolerability of nab-paclitaxel monotherapy in paediatric patients with recurrent or refractory solid tumours. The activity and safety of nab-paclitaxel monotherapy was further investigated in this phase II study. Paediatric Elsevier Ewing sarcoma Elsevier Rhabdomyosarcoma Elsevier Solid tumour Elsevier Neuroblastoma Elsevier Albumin-bound paclitaxel Elsevier Castel, Victoria oth Bisogno, Gianni oth Casanova, Michela oth Marquez-Vega, Catalina oth Chisholm, Julia C. oth Doz, François oth Moreno, Lucas oth Ruggiero, Antonio oth Gerber, Nicolas U. oth Fagioli, Franca oth Hingorani, Pooja oth Melcón, Soledad G. oth Slepetis, Ruta oth Chen, Nianhang oth le Bruchec, Yvan oth Simcock, Mathew oth Vassal, Gilles oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:135 year:2020 pages:89-97 extent:9 https://doi.org/10.1016/j.ejca.2020.04.031 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 135 2020 89-97 9 |
allfields_unstemmed |
10.1016/j.ejca.2020.04.031 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001600.pica (DE-627)ELV050852124 (ELSEVIER)S0959-8049(20)30234-3 DE-627 ger DE-627 rakwb eng 610 VZ 44.52 bkl Amoroso, Loredana verfasserin aut Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network 2020 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The phase I component of a phase I/II study defined the recommended phase II dose and established the tolerability of nab-paclitaxel monotherapy in paediatric patients with recurrent or refractory solid tumours. The activity and safety of nab-paclitaxel monotherapy was further investigated in this phase II study. Paediatric Elsevier Ewing sarcoma Elsevier Rhabdomyosarcoma Elsevier Solid tumour Elsevier Neuroblastoma Elsevier Albumin-bound paclitaxel Elsevier Castel, Victoria oth Bisogno, Gianni oth Casanova, Michela oth Marquez-Vega, Catalina oth Chisholm, Julia C. oth Doz, François oth Moreno, Lucas oth Ruggiero, Antonio oth Gerber, Nicolas U. oth Fagioli, Franca oth Hingorani, Pooja oth Melcón, Soledad G. oth Slepetis, Ruta oth Chen, Nianhang oth le Bruchec, Yvan oth Simcock, Mathew oth Vassal, Gilles oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:135 year:2020 pages:89-97 extent:9 https://doi.org/10.1016/j.ejca.2020.04.031 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 135 2020 89-97 9 |
allfieldsGer |
10.1016/j.ejca.2020.04.031 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001600.pica (DE-627)ELV050852124 (ELSEVIER)S0959-8049(20)30234-3 DE-627 ger DE-627 rakwb eng 610 VZ 44.52 bkl Amoroso, Loredana verfasserin aut Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network 2020 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The phase I component of a phase I/II study defined the recommended phase II dose and established the tolerability of nab-paclitaxel monotherapy in paediatric patients with recurrent or refractory solid tumours. The activity and safety of nab-paclitaxel monotherapy was further investigated in this phase II study. Paediatric Elsevier Ewing sarcoma Elsevier Rhabdomyosarcoma Elsevier Solid tumour Elsevier Neuroblastoma Elsevier Albumin-bound paclitaxel Elsevier Castel, Victoria oth Bisogno, Gianni oth Casanova, Michela oth Marquez-Vega, Catalina oth Chisholm, Julia C. oth Doz, François oth Moreno, Lucas oth Ruggiero, Antonio oth Gerber, Nicolas U. oth Fagioli, Franca oth Hingorani, Pooja oth Melcón, Soledad G. oth Slepetis, Ruta oth Chen, Nianhang oth le Bruchec, Yvan oth Simcock, Mathew oth Vassal, Gilles oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:135 year:2020 pages:89-97 extent:9 https://doi.org/10.1016/j.ejca.2020.04.031 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 135 2020 89-97 9 |
allfieldsSound |
10.1016/j.ejca.2020.04.031 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001600.pica (DE-627)ELV050852124 (ELSEVIER)S0959-8049(20)30234-3 DE-627 ger DE-627 rakwb eng 610 VZ 44.52 bkl Amoroso, Loredana verfasserin aut Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network 2020 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The phase I component of a phase I/II study defined the recommended phase II dose and established the tolerability of nab-paclitaxel monotherapy in paediatric patients with recurrent or refractory solid tumours. The activity and safety of nab-paclitaxel monotherapy was further investigated in this phase II study. Paediatric Elsevier Ewing sarcoma Elsevier Rhabdomyosarcoma Elsevier Solid tumour Elsevier Neuroblastoma Elsevier Albumin-bound paclitaxel Elsevier Castel, Victoria oth Bisogno, Gianni oth Casanova, Michela oth Marquez-Vega, Catalina oth Chisholm, Julia C. oth Doz, François oth Moreno, Lucas oth Ruggiero, Antonio oth Gerber, Nicolas U. oth Fagioli, Franca oth Hingorani, Pooja oth Melcón, Soledad G. oth Slepetis, Ruta oth Chen, Nianhang oth le Bruchec, Yvan oth Simcock, Mathew oth Vassal, Gilles oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:135 year:2020 pages:89-97 extent:9 https://doi.org/10.1016/j.ejca.2020.04.031 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 135 2020 89-97 9 |
language |
English |
source |
Enthalten in The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study Amsterdam [u.a.] volume:135 year:2020 pages:89-97 extent:9 |
sourceStr |
Enthalten in The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study Amsterdam [u.a.] volume:135 year:2020 pages:89-97 extent:9 |
format_phy_str_mv |
Article |
bklname |
Therapie |
institution |
findex.gbv.de |
topic_facet |
Paediatric Ewing sarcoma Rhabdomyosarcoma Solid tumour Neuroblastoma Albumin-bound paclitaxel |
dewey-raw |
610 |
isfreeaccess_bool |
false |
container_title |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
authorswithroles_txt_mv |
Amoroso, Loredana @@aut@@ Castel, Victoria @@oth@@ Bisogno, Gianni @@oth@@ Casanova, Michela @@oth@@ Marquez-Vega, Catalina @@oth@@ Chisholm, Julia C. @@oth@@ Doz, François @@oth@@ Moreno, Lucas @@oth@@ Ruggiero, Antonio @@oth@@ Gerber, Nicolas U. @@oth@@ Fagioli, Franca @@oth@@ Hingorani, Pooja @@oth@@ Melcón, Soledad G. @@oth@@ Slepetis, Ruta @@oth@@ Chen, Nianhang @@oth@@ le Bruchec, Yvan @@oth@@ Simcock, Mathew @@oth@@ Vassal, Gilles @@oth@@ |
publishDateDaySort_date |
2020-01-01T00:00:00Z |
hierarchy_top_id |
ELV000241849 |
dewey-sort |
3610 |
id |
ELV050852124 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV050852124</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624170346.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200722s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejca.2020.04.031</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001600.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV050852124</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0959-8049(20)30234-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Amoroso, Loredana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The phase I component of a phase I/II study defined the recommended phase II dose and established the tolerability of nab-paclitaxel monotherapy in paediatric patients with recurrent or refractory solid tumours. The activity and safety of nab-paclitaxel monotherapy was further investigated in this phase II study.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Paediatric</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ewing sarcoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Rhabdomyosarcoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Solid tumour</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neuroblastoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Albumin-bound paclitaxel</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Castel, Victoria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bisogno, Gianni</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Casanova, Michela</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marquez-Vega, Catalina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chisholm, Julia C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Doz, François</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moreno, Lucas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ruggiero, Antonio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gerber, Nicolas U.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fagioli, Franca</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hingorani, Pooja</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Melcón, Soledad G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Slepetis, Ruta</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Nianhang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">le Bruchec, Yvan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Simcock, Mathew</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vassal, Gilles</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Hamzah, N. ELSEVIER</subfield><subfield code="t">The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000241849</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:135</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:89-97</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejca.2020.04.031</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">135</subfield><subfield code="j">2020</subfield><subfield code="h">89-97</subfield><subfield code="g">9</subfield></datafield></record></collection>
|
author |
Amoroso, Loredana |
spellingShingle |
Amoroso, Loredana ddc 610 bkl 44.52 Elsevier Paediatric Elsevier Ewing sarcoma Elsevier Rhabdomyosarcoma Elsevier Solid tumour Elsevier Neuroblastoma Elsevier Albumin-bound paclitaxel Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network |
authorStr |
Amoroso, Loredana |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000241849 |
format |
electronic Article |
dewey-ones |
610 - Medicine & health |
delete_txt_mv |
keep |
author_role |
aut |
collection |
elsevier |
remote_str |
true |
illustrated |
Not Illustrated |
topic_title |
610 VZ 44.52 bkl Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network Paediatric Elsevier Ewing sarcoma Elsevier Rhabdomyosarcoma Elsevier Solid tumour Elsevier Neuroblastoma Elsevier Albumin-bound paclitaxel Elsevier |
topic |
ddc 610 bkl 44.52 Elsevier Paediatric Elsevier Ewing sarcoma Elsevier Rhabdomyosarcoma Elsevier Solid tumour Elsevier Neuroblastoma Elsevier Albumin-bound paclitaxel |
topic_unstemmed |
ddc 610 bkl 44.52 Elsevier Paediatric Elsevier Ewing sarcoma Elsevier Rhabdomyosarcoma Elsevier Solid tumour Elsevier Neuroblastoma Elsevier Albumin-bound paclitaxel |
topic_browse |
ddc 610 bkl 44.52 Elsevier Paediatric Elsevier Ewing sarcoma Elsevier Rhabdomyosarcoma Elsevier Solid tumour Elsevier Neuroblastoma Elsevier Albumin-bound paclitaxel |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
zu |
author2_variant |
v c vc g b gb m c mc c m v cmv j c c jc jcc f d fd l m lm a r ar n u g nu nug f f ff p h ph s g m sg sgm r s rs n c nc b y l by byl m s ms g v gv |
hierarchy_parent_title |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
hierarchy_parent_id |
ELV000241849 |
dewey-tens |
610 - Medicine & health |
hierarchy_top_title |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)ELV000241849 |
title |
Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network |
ctrlnum |
(DE-627)ELV050852124 (ELSEVIER)S0959-8049(20)30234-3 |
title_full |
Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network |
author_sort |
Amoroso, Loredana |
journal |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
journalStr |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology |
recordtype |
marc |
publishDateSort |
2020 |
contenttype_str_mv |
zzz |
container_start_page |
89 |
author_browse |
Amoroso, Loredana |
container_volume |
135 |
physical |
9 |
class |
610 VZ 44.52 bkl |
format_se |
Elektronische Aufsätze |
author-letter |
Amoroso, Loredana |
doi_str_mv |
10.1016/j.ejca.2020.04.031 |
dewey-full |
610 |
title_sort |
phase ii results from a phase i/ii study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: a collaboration with the european innovative therapies for children with cancer network |
title_auth |
Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network |
abstract |
The phase I component of a phase I/II study defined the recommended phase II dose and established the tolerability of nab-paclitaxel monotherapy in paediatric patients with recurrent or refractory solid tumours. The activity and safety of nab-paclitaxel monotherapy was further investigated in this phase II study. |
abstractGer |
The phase I component of a phase I/II study defined the recommended phase II dose and established the tolerability of nab-paclitaxel monotherapy in paediatric patients with recurrent or refractory solid tumours. The activity and safety of nab-paclitaxel monotherapy was further investigated in this phase II study. |
abstract_unstemmed |
The phase I component of a phase I/II study defined the recommended phase II dose and established the tolerability of nab-paclitaxel monotherapy in paediatric patients with recurrent or refractory solid tumours. The activity and safety of nab-paclitaxel monotherapy was further investigated in this phase II study. |
collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
title_short |
Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network |
url |
https://doi.org/10.1016/j.ejca.2020.04.031 |
remote_bool |
true |
author2 |
Castel, Victoria Bisogno, Gianni Casanova, Michela Marquez-Vega, Catalina Chisholm, Julia C. Doz, François Moreno, Lucas Ruggiero, Antonio Gerber, Nicolas U. Fagioli, Franca Hingorani, Pooja Melcón, Soledad G. Slepetis, Ruta Chen, Nianhang le Bruchec, Yvan Simcock, Mathew Vassal, Gilles |
author2Str |
Castel, Victoria Bisogno, Gianni Casanova, Michela Marquez-Vega, Catalina Chisholm, Julia C. Doz, François Moreno, Lucas Ruggiero, Antonio Gerber, Nicolas U. Fagioli, Franca Hingorani, Pooja Melcón, Soledad G. Slepetis, Ruta Chen, Nianhang le Bruchec, Yvan Simcock, Mathew Vassal, Gilles |
ppnlink |
ELV000241849 |
mediatype_str_mv |
z |
isOA_txt |
false |
hochschulschrift_bool |
false |
author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
doi_str |
10.1016/j.ejca.2020.04.031 |
up_date |
2024-07-06T18:38:56.091Z |
_version_ |
1803855998318804992 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV050852124</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624170346.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200722s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejca.2020.04.031</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001600.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV050852124</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0959-8049(20)30234-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Amoroso, Loredana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The phase I component of a phase I/II study defined the recommended phase II dose and established the tolerability of nab-paclitaxel monotherapy in paediatric patients with recurrent or refractory solid tumours. The activity and safety of nab-paclitaxel monotherapy was further investigated in this phase II study.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Paediatric</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ewing sarcoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Rhabdomyosarcoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Solid tumour</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neuroblastoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Albumin-bound paclitaxel</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Castel, Victoria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bisogno, Gianni</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Casanova, Michela</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marquez-Vega, Catalina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chisholm, Julia C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Doz, François</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moreno, Lucas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ruggiero, Antonio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gerber, Nicolas U.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fagioli, Franca</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hingorani, Pooja</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Melcón, Soledad G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Slepetis, Ruta</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Nianhang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">le Bruchec, Yvan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Simcock, Mathew</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vassal, Gilles</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Hamzah, N. ELSEVIER</subfield><subfield code="t">The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000241849</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:135</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:89-97</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejca.2020.04.031</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">135</subfield><subfield code="j">2020</subfield><subfield code="h">89-97</subfield><subfield code="g">9</subfield></datafield></record></collection>
|
score |
7.3994513 |